“…The 5% recurrence rate demonstrated in this series, particularly with juxtaphyseal lesions, provides an acceptable comparative recurrence rate [1,11,16,17,25,28,33,35,36,42,44] with which to pursue further study of this percutaneous treatment option. Furthermore, when recurrence (evidence of residual foci of tumor cells) occurs, patients are able to pursue a minimally invasive option of percutaneous treatment of small recurrent foci.…”